Literature DB >> 30026331

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis.

Tamer B Shabaneh1, Aleksey K Molodtsov1, Shannon M Steinberg1, Peisheng Zhang1, Gretel M Torres1, Gadisti A Mohamed1, Andrea Boni2, Tyler J Curiel3, Christina V Angeles4,5, Mary Jo Turk6,5.   

Abstract

Regulatory T cells (Treg) are critical mediators of immunosuppression in established tumors, although little is known about their role in restraining immunosurveillance during tumorigenesis. Here, we employ an inducible autochthonous model of melanoma to investigate the earliest Treg and CD8 effector T-cell responses during oncogene-driven tumorigenesis. Induction of oncogenic BRAFV600E and loss of Pten in melanocytes led to localized accumulation of FoxP3+ Tregs, but not CD8 T cells, within 1 week of detectable increases in melanocyte differentiation antigen expression. Melanoma tumorigenesis elicited early expansion of shared tumor/self-antigen-specific, thymically derived Tregs in draining lymph nodes, and induced their subsequent recruitment to sites of tumorigenesis in the skin. Lymph node egress of tumor-activated Tregs was required for their C-C chemokine receptor 4 (Ccr4)-dependent homing to nascent tumor sites. Notably, BRAFV600E signaling controlled expression of Ccr4-cognate chemokines and governed recruitment of Tregs to tumor-induced skin sites. BRAFV600E expression alone in melanocytes resulted in nevus formation and associated Treg recruitment, indicating that BRAFV600E signaling is sufficient to recruit Tregs. Treg depletion liberated immunosurveillance, evidenced by CD8 T-cell responses against the tumor/self-antigen gp100, which was concurrent with the formation of microscopic neoplasia. These studies establish a novel role for BRAFV600E as a tumor cell-intrinsic mediator of immune evasion and underscore the critical early role of Treg-mediated suppression during autochthonous tumorigenesis.Significance: This work provides new insights into the mechanisms by which oncogenic pathways impact immune regulation in the nascent tumor microenvironment. Cancer Res; 78(17); 5038-49. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30026331      PMCID: PMC6319620          DOI: 10.1158/0008-5472.CAN-18-0365

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Authors:  Rebecca A Evans; Mark S Diamond; Andrew J Rech; Timothy Chao; Max W Richardson; Jeffrey H Lin; David L Bajor; Katelyn T Byrne; Ben Z Stanger; James L Riley; Nune Markosyan; Rafael Winograd; Robert H Vonderheide
Journal:  JCI Insight       Date:  2016-09-08

2.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

3.  Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.

Authors:  J Liu; K G Suresh Kumar; D Yu; S A Molton; M McMahon; M Herlyn; A Thomas-Tikhonenko; S Y Fuchs
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

4.  BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Authors:  Chrysiis Michaloglou; Liesbeth C W Vredeveld; Maria S Soengas; Christophe Denoyelle; Thomas Kuilman; Chantal M A M van der Horst; Donné M Majoor; Jerry W Shay; Wolter J Mooi; Daniel S Peeper
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  Aire-dependent thymic development of tumor-associated regulatory T cells.

Authors:  Sven Malchow; Daniel S Leventhal; Saki Nishi; Benjamin I Fischer; Lynn Shen; Gladell P Paner; Ayelet S Amit; Chulho Kang; Jenna E Geddes; James P Allison; Nicholas D Socci; Peter A Savage
Journal:  Science       Date:  2013-03-08       Impact factor: 47.728

6.  Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.

Authors:  V Mourmouras; M Fimiani; P Rubegni; M C Epistolato; V Malagnino; C Cardone; E Cosci; M C De Nisi; C Miracco
Journal:  Br J Dermatol       Date:  2007-06-26       Impact factor: 9.302

7.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

Authors:  Sjoerd H van der Burg; Sytse J Piersma; Annemieke de Jong; Jeanette M van der Hulst; Kitty M C Kwappenberg; Muriel van den Hende; Marij J P Welters; Jon J Van Rood; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Rienk Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-05       Impact factor: 11.205

8.  Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.

Authors:  Amedeo Amedei; Elena Niccolai; Marisa Benagiano; Chiara Della Bella; Fabio Cianchi; Paolo Bechi; Antonio Taddei; Lapo Bencini; Marco Farsi; Paola Cappello; Domenico Prisco; Francesco Novelli; Mario Milco D'Elios
Journal:  Cancer Immunol Immunother       Date:  2013-05-03       Impact factor: 6.968

9.  Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

Authors:  Vinod P Balachandran; Michael J Cavnar; Shan Zeng; Zubin M Bamboat; Lee M Ocuin; Hebroon Obaid; Eric C Sorenson; Rachel Popow; Charlotte Ariyan; Ferdinand Rossi; Peter Besmer; Tianhua Guo; Cristina R Antonescu; Takahiro Taguchi; Jianda Yuan; Jedd D Wolchok; James P Allison; Ronald P DeMatteo
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

Review 10.  Transcriptional regulation of chemokine expression in ovarian cancer.

Authors:  Bipradeb Singha; Himavanth R Gatla; Ivana Vancurova
Journal:  Biomolecules       Date:  2015-03-17
View more
  25 in total

Review 1.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 2.  Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Authors:  Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley
Journal:  Semin Cancer Biol       Date:  2019-11-02       Impact factor: 15.707

Review 3.  Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.

Authors:  Haley du Bois; Taylor A Heim; Amanda W Lund
Journal:  Sci Immunol       Date:  2021-09-03

4.  Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.

Authors:  R R Maniyar; S Chakraborty; T Jarboe; R Suriano; M Wallack; J Geliebter; R K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis.

Authors:  Qing Bi; Ji-Yue Wu; Xue-Meng Qiu; Jian-Dong Zhang; Ze-Jia Sun; Wei Wang
Journal:  J Immunol Res       Date:  2022-06-13       Impact factor: 4.493

Review 6.  Chemokines and the immune response to cancer.

Authors:  Aleksandra J Ozga; Melvyn T Chow; Andrew D Luster
Journal:  Immunity       Date:  2021-04-10       Impact factor: 31.745

7.  Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.

Authors:  Manali S Phadke; Zhihua Chen; Jiannong Li; Eslam Mohamed; Michael A Davies; Inna Smalley; Derek R Duckett; Vinayak Palve; Brian J Czerniecki; Peter A Forsyth; David Noyes; Dennis O Adeegbe; Zeynep Eroglu; Kimberly T Nguyen; Kenneth Y Tsai; Uwe Rix; Christin E Burd; Yian A Chen; Paulo C Rodriguez; Keiran S M Smalley
Journal:  Cancer Immunol Res       Date:  2021-03-02       Impact factor: 12.020

Review 8.  Strategies to Develop a Suitable Formulation for Inflammatory Skin Disease Treatment.

Authors:  Jiun-Wen Guo; Shiou-Hwa Jee
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.

Authors:  Asumi Iesato; Stephanie Li; Giovanni Roti; Michele R Hacker; Andrew H Fischer; Carmelo Nucera
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

Review 10.  Liver Tropism in Cancer: The Hepatic Metastatic Niche.

Authors:  Ainhoa Mielgo; Michael C Schmid
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.